Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AL-102 by Immunome for Benign Tumor: Likelihood of Approval
AL-102 is under clinical development by Immunome and currently in Phase III for Benign Tumor. According to GlobalData, Phase III...